A research paper by Delinda Johnson, a pharmaceutical sciences researcher, is highlighted in the April issue of Toxicological Sciences.

The paper addresses how the pro-antioxidant transcription factor Nrf2 attenuates experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. The studies strongly support the concept of Nrf2 activation being a viable drug target for the treatment of multiple sclerosis and potentially other autoimmune diseases.

Toxicological Sciences publishes approximately 400 papers a year and highlights only one paper a month. Commentary by peer reviewers was also available. School of Pharmacy colleagues, Sara Amirahmadi, associate research specialist, and Jeff Johnson, professor in the Pharmaceutical Sciences Division, along with Charlotte Ward, and Zsuszanna Fabry, Department of Pathology and Laboratory Medicine, are co-authors on the paper.

The mission of Toxicological Sciences, the official journal of the Society of Toxicology, is to publish premier peer-reviewed, hypothesis-driven, original research articles in all areas of toxicology.